Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience operating margin
Operating margin is operating income as a percentage of revenue.
Twist Bioscience's operating margin for the twelve months ending Jun 30, 2026 was -33.6%. For fiscal 2025 it was -36.2%, against -70.6% the year before. The highest annual figure on record is -36.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -36.2% | +34.4 |
| FY2024 | Sep 30, 2024 | -70.6% | +18.0 |
| FY2023 | Sep 30, 2023 | -88.6% | +26.7 |
| FY2022 | Sep 30, 2022 | -115.3% | +0.1 |
| FY2021 | Sep 30, 2021 | -115.4% | +40.1 |
| FY2020 | Sep 30, 2020 | -155.5% | +44.7 |
| FY2019 | Sep 30, 2019 | -200.1% | +77.3 |
| FY2018 | Sep 30, 2018 | -277.5% | +265.7 |
| FY2017 | Sep 30, 2017 | -543.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -30.6% | +0.7 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -41.4% | +3.4 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -31.7% | +7.3 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -30.2% | +12.3 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -31.4% | +77.8 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -44.8% | +20.1 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -39.1% | +26.7 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -42.5% | +32.3 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -109.2% | −13.8 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -64.9% | +37.5 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -65.7% | +16.6 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -74.9% | +24.4 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -95.4% | +13.6 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -102.4% | +23.9 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -82.3% | +50.9 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -99.2% | +5.7 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -109.0% | +11.3 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -126.3% | −4.5 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -133.1% | −16.7 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -104.9% | −31.0 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -120.3% | +12.7 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -121.8% | +44.5 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -116.4% | +208.8 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -73.9% | +126.7 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -133.0% | +73.8 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -166.3% | +27.4 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -325.3% | −126.0 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -200.6% | +33.8 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -206.8% | +60.6 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -193.7% | +75.8 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -199.2% | +189.1 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -234.4% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -267.3% | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -269.5% | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -388.4% | – |
See a number that looks wrong?